Cochlear Ltd (COH)
Australian Securities Exchange · Australia · prices in AUD · close of 23 Oct 2026
Key indicators
| Last close | AUD 146.81 |
|---|---|
| 52-week range | 88.74 – 296.50 |
| Return, 1 month / 3 months | +4.3% / +32.2% |
| Return, 1 year / 3 years | −48.5% / −37.6% |
| Trend | Below its 200-day average |
| RSI (14) | 69 |
| Volatility (1 year) | 64.4% |
| Worst drawdown (1 year) | -69.2% |
| Average daily value traded | 81.42M AUD |
| Dividend yield | 2.4% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cochlear makes implantable hearing solutions for people with moderate to profound hearing loss. Its products include cochlear implant systems, bone conduction hearing devices and related sound processors and accessories, sold to hospitals, clinics and hearing care professionals who fit them for patients. The company is based in Australia and serves customers in many countries around the world through its own staff and distribution partners.
The shares are listed on the Australian Securities Exchange in Australia under the code COH, and the price on this page is in Australian dollars (AUD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cochlear Ltd (COH) trades on the Australian Securities Exchange in Australia. It last closed at AUD 146.81 on 23 October 2026.
Its price-based Market X-Ray is 60 out of 100 (a fair price profile), ranking 651 of 1,816 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 48.5% and over the last three months it rose 32.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 55 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -0.6% | ||
| From 52-week high | -50.4% | ||
| Momentum | 70 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 32.2% | ||
| 6-month return | 56.1% | ||
| 12-month return, skipping the last month | -50.6% | ||
| Stability (higher is calmer) | 42 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 64.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -69.2% | ||
| Liquidity | 99 · Strong | Trades actively. | |
| Average daily value traded | 81.42M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | 36 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.4% | ||
| Years with dividends | 5 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Income: Dividend is small or irregular.
Returns
| 1 week | +12.0% |
|---|---|
| 1 month | +4.3% |
| 3 months | +32.2% |
| 6 months | +56.1% |
| 1 year | −48.5% |
| 3 years | −37.6% |
| 5 years | −28.7% |
Signals
| 50-day / 200-day average | 135.59 / 147.76 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 4.41 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 21 Sep 2026 | AUD 1.3000 |
| 19 Mar 2026 | AUD 2.1500 |
| 18 Sep 2025 | AUD 2.1500 |
| 20 Mar 2025 | AUD 2.1500 |
| 17 Sep 2024 | AUD 2.1000 |
| 21 Mar 2024 | AUD 2.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.